Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

$14.68 +0.04 (+0.24%)

Closing price 04/17/2025 03:59 PM Eastern

Extended Trading

$14.63 -0.05 (-0.37%)

As of 04/17/2025 05:19 PM Eastern

Takeda Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 1 Analyst Ratings

Sell
0

Hold
0

Buy
1

Based on 1 Wall Street analysts who have issued ratings for Takeda Pharmaceutical in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for TAK.

Consensus Price Target

N/A

Get the Latest News and Ratings for TAK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors.

TAK Analyst Ratings Over Time

Type	Current Forecast 4/18/24 to 4/18/25	1 Month Ago 3/19/24 to 3/19/25	3 Months Ago 1/19/24 to 1/18/25	1 Year Ago 4/19/23 to 4/18/24
Strong Buy	0 Strong Buy rating(s)	N/A	N/A	N/A
Buy	1 Buy rating(s)	N/A	N/A	N/A
Hold	0 Hold rating(s)	N/A	N/A	N/A
Sell	0 Sell rating(s)	N/A	N/A	N/A
Consensus Price Target	N/A	N/A	N/A	$14.00
Forecasted Upside	N/A	N/A	N/A	6.38% Upside
Consensus Rating	Buy	N/A	N/A	N/A

TAK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TAK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Takeda Pharmaceutical Stock vs. The Competition

Type	Takeda Pharmaceutical	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	N/A	21,675.80% Upside	26.48% Upside
News Sentiment Rating	Positive News See Recent TAK News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date	Details
4/2/2025	Morgan Stanley 3 of 5 stars		Upgrade	Equal Weight ➝ Overweight
9/1/2023	JPMorgan Chase & Co. 3 of 5 stars		Lower Target		$14.20 ➝ $14.00	-9.06%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:24 PM ET.

Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, April 14, 2025. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

Takeda Pharmaceutical
Bull Case

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

Recent earnings performance shows strength, with a reported earnings per share (EPS) of $0.42, exceeding analysts' expectations of $0.34, indicating robust financial health and potential for future growth.
The stock is currently priced at $15.00, which is near its 12-month high of $15.31, suggesting strong market confidence and potential for further appreciation.
Takeda Pharmaceutical Company Limited has a solid return on equity of 9.39%, reflecting effective management and the ability to generate profits from shareholders' equity.
Institutional interest is growing, with significant investments from firms like Boston Partners, which recently acquired shares valued at approximately $915,000, indicating confidence from large investors.
The company has a favorable price-to-earnings (P/E) ratio of 37.49, which, while high, can be justified by its growth potential in the pharmaceutical sector.

Takeda Pharmaceutical
Bear Case

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

The stock has experienced a slight decline of 0.3%, which may indicate short-term volatility and investor uncertainty.
With a net margin of only 4.53%, the company may face challenges in maintaining profitability, which could affect future earnings.
The current debt-to-equity ratio of 0.63 suggests that the company has a moderate level of debt, which could pose risks if market conditions change.
Despite recent positive earnings, the price-to-earnings-growth (PEG) ratio of 0.24 indicates that the stock may be overvalued relative to its growth rate, which could deter value-focused investors.
Market fluctuations and regulatory changes in the pharmaceutical industry can impact Takeda Pharmaceutical's operations and profitability, adding an element of risk for investors.

TAK Forecast - Frequently Asked Questions

: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TAK shares.
: According to analysts, Takeda Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Takeda Pharmaceutical's stock had 1 upgrade by analysts.
: Takeda Pharmaceutical has been rated by research analysts at Morgan Stanley in the past 90 days.
: Analysts like Takeda Pharmaceutical more than other "medical" companies. The consensus rating for Takeda Pharmaceutical is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TAK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:TAK) was last updated on 4/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Stock Forecast & Price Target